Ken Poole is an academic rheumatologist at the University of Cambridge, applying novel imaging techniques to investigate human bone diseases. Research in his group focuses on osteoporotic fragility fractures and osteoarthritis by studying micro and macroscopic bone structure in health and disease. With Graham Treece and Andrew Gee from the University Engineering department he pioneered a way of assessing the 3D structure of bone structure in life called Cortical Bone Mapping (CBM), based on clinical Computed Tomography (CT). They have used CBM, histology and microCT to discover that there are defined patches of focal osteoporosis in older people’s femurs that predispose them to hip fracture. Bone mapping measurements from clinical CT predict hip fractures well. Analysing separate clinical trials, they studied serial CT scans of hips and vertebrae to show the precise treatment effects of teriparatide, romosozumab and denosumab. Other publications since Ken's PhD thesis (Clare college, Cambridge 2006) have included a successful RCT using zoledronate to prevent bone loss after stroke and a study of osteocytes as the master regulators of bone formation via sclerostin (cited more than 750 times). This work has led to various advisory roles on anti-sclerostin therapies in osteoporosis and osteogenesis imperfecta. He also studies the opportunistic identification of osteoporosis in routine CT imaging data as Chief Investigator of the PHOENIX study.